High Income DIY Portfolios: The primary goal of "High Income DIY Portfolios" Marketplace service is high income with low risk and preservation of capital. It provides DIY investors with vital information and portfolio/asset allocation strategies to help create stable, long-term passive income with sustainable yields. The portfolios are designed for Income-Investors (including retirees or near-retirees). We provide seven portfolios: 3 buy-and-hold, 3 Rotational portfolios, and 3-Bucket NPP Model Portfolio. T ...

Key Takeaways Johnson & Johnson posted 4.6% Q2 operational sales growth despite STELARA losing exclusivity.JNJ's diverse portfolio and $6B free cash flow support steady returns and shareholder value.Apple's Q3 sales rose on new iPhones and record Services revenue, with device usage hitting a high.In a well-balanced retirement portfolio, investors should aim for a mix of defensive and growth stocks. This approach offers both stability and the potential for wealth creation over time. By investing in Johnson & ...

2025年2月，该药首次在国内获批，用于EGFRex20ins突变NSCLC一线治疗。2025年4月，该药在国内获批一项 新适应症，联合化疗用于EGFRTKI经治后局部晚期或转移性NSCLC患者治疗。本次是埃万妥单抗在国内获批的 第3项适应症。 埃万妥单抗最早于2021年5月在美国首次获得加速批准上市。迄今，围绕非小细胞肺癌这一重磅癌种，埃万妥单 抗在全球范围内已获批4项适应症 智通财经APP获悉，8月8日，强生(JNJ.US)宣布EGFR/c-MET双抗"埃万妥单抗"(Amivantamab)在国内获批一项新 适应症，联合兰泽替尼适用于携带表皮生长因子受体(EGFR)19号外显子缺失或21号外显子L858R置换突变的局 部晚期或转移性非小细胞肺癌(NSCLC)成人患者的一线治疗。 ...

August 4, 2025 12:27 PM GMT Biopharma | North America A picture is worth a thousand words Comprehensive US drug market analysis (IQVIA Rx). The latest weekly Total Prescription YoY growth (wk ending 7/25) was +1.7% vs. +3.0% last wk and +2.6% over the past 12 wks. For week ended Jul 25, US total market weekly TRx YoY change was +1.7% vs. +1.7% year ago ( Exhibit7 ). Rolling 4-week TRx YoY was +3.0% and rolling 12-week TRx YoY was +2.6%. Extended unit (EUTRx) weekly YoY growth was +0.9%, below TRx YoY ( Exhi ...

A retired federal judge will help decide the fate of thousands of Johnson & Johnson baby powder cancer lawsuits even though her law firm represents the drugmaker in other matters https://t.co/BJbitrn0XR ...

一些分析师估计，如果美国对欧盟出口到美国的药品征收15%的关税，这可能会使整个制药行业每年增加高达190亿美元的成本。 此前，特朗普还向17家制药公司发函，要求他们降低在美国药品的售价，这些公司包括礼来、强生、阿斯利康、诺和诺德、再生元、赛诺菲、艾伯维、辉 瑞、诺华、默沙东等。 每经编辑｜程鹏 当地时间8月6日，美国总统特朗普表示，美国将对芯片和半导体征收约100%的关税。 特朗普称，如果在美国制造，将不收取任何费用。 另外，当地时间8月5日，美国总统特朗普在接受美国消费者新闻与商业频道（CNBC）采访时表示，美国将首先对进口药品征收"小额关税"，并在一年左 右的时间内提高税率。 他表示："一年，最多一年半，税率将升至150%，之后将升至250%，因为我们希望药品在我们国家生产。"但他没有透露药品的初始关税税率是多少。 不过，市场平淡消化了这一消息，多家企业在近期财报中表示，关税预计在今年将不会对公司业绩产生重大影响。当天（5日）美股收盘，辉瑞股价上涨 超5%，礼来、强生等公司股价略有下跌。 编辑|程鹏 杜恒峰 校对|刘思琦 封面图片来源：视觉中国（资料图） 每日经济新闻综合自央视新闻、第一财经 ...

All investors love getting big returns from their portfolio, whether it's through stocks, bonds, ETFs, or other types of securities. But when you're an income investor, your primary focus is generating consistent cash flow from each of your liquid investments.While cash flow can come from bond interest or interest from other types of investments, income investors hone in on dividends. A dividend is the distribution of a company's earnings paid out to shareholders; it's often viewed by its dividend yield, a ...

But in my view, that number is less important than how the stock has responded to the growing fearsWith over two decades of dedicated experience in investment, Allka Research has been a guiding force for individuals seeking lucrative opportunities. Its conservative approach sets it apart, consistently unearthing undervalued assets within the realms of ETFs, commodities, technology, and pharmaceutical companies.Allka Research's journey in the investment landscape is marked by a commitment to delivering subst ...

Core Insights - Johnson & Johnson (JNJ) reported strong second-quarter results, exceeding earnings and sales estimates despite the loss of exclusivity for its drug Stelara [1][2] - The company raised its 2025 sales expectations by approximately $2.0 billion, reflecting robust operational performance and favorable currency impacts [2][3] - JNJ's sales guidance for 2025 was adjusted from $91.0 billion-$91.8 billion to $93.2 billion-$93.4 billion, indicating a growth rate of 5.1%-5.6% compared to the previous expectation of 2.6%-3.6% [3] - Adjusted earnings per share guidance was increased from $10.50-$10.70 to $10.80-$10.90, supported by top-line strength and reduced tariff costs [3] Innovative Medicine Segment - JNJ anticipates higher operational sales growth in the Innovative Medicine segment in the second half of the year, driven by key products like Darzalex, Tremfya, and new drugs such as Carvykti and Tecvayli [4][5] - The impact of Stelara's loss of exclusivity and Medicare Part D redesign is expected to be mitigated by the performance of newly launched products [4] MedTech Segment - The MedTech segment is expected to see growth driven by increased adoption of new products in Cardiovascular, Surgery, and Vision, although challenges in China may persist [5] - Sales in the MedTech segment are projected to be stronger in the second half of the year as the business overcomes tougher comparisons from the first half [5] Market Performance - JNJ's shares have outperformed the industry year-to-date, with a 17.6% increase compared to a 3.3% decline in the industry [8] - The company's stock is currently trading at a price/earnings ratio of 15.0, slightly above the industry average of 14.29 but below its five-year mean of 15.68 [10] Earnings Estimates - The Zacks Consensus Estimate for JNJ's 2025 earnings has increased from $10.62 to $10.86 over the past 30 days, while the estimate for 2026 has risen from $11.0 to $11.36 [11]

Group 1 - President Trump issued a stern ultimatum to 17 pharmaceutical companies, demanding they take measures to lower drug prices in the U.S. within 60 days, or face government intervention [1][3] - The ultimatum is part of an executive order signed by Trump in May, aimed at reviving the "most favored nation" pricing policy, which links U.S. drug prices to lower prices in other countries [3] - Current data shows that the average price of prescription drugs in the U.S. is typically 2 to 3 times higher than in other developed countries, with some drug prices being as much as 10 times higher [3] Group 2 - Following the announcement, pharmaceutical stocks experienced significant declines, with Sanofi dropping over 7%, Novo Nordisk falling nearly 6% to a four-year low, and other companies like Bristol-Myers Squibb and Merck seeing declines of over 4% [4] - The pharmaceutical industry reacted strongly, with the American Pharmaceutical Research and Manufacturers Association stating that foreign price control measures would undermine U.S. leadership in the sector [4] - Some companies are adjusting their strategies in response, with Novo Nordisk emphasizing its commitment to improving patient access, Pfizer collaborating with Congress and the White House, and Merck expressing willingness to work with the government to achieve price reduction goals [4]